First Patient Dosed in the ENLIGHTEN Biomarker-Guided Global Clinical Trial of DB104 (Liafensine) for Treatment-Resistant Depression

SAN DIEGO, July 28, 2022 /PRNewswire/ — Denovo Biopharma LLC (“Denovo”), a pioneer in applying precision medicine to the development of innovative therapies, today announced dosing of the first patient in its biomarker-guided global Phase 2b clinical trial (the “ENLIGHTEN” study) to…

Click here to view original post